Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 94,819 | 176,210 | 181,095 | 193,705 | 224,947 |
| Marketable Securities | 196,557 | 140,742 | 142,485 | 104,819 | 2,495 |
| Receivables | 48,059 | 30,304 | 30,841 | 31,361 | 17,714 |
| Inventories | 2,620 | 2,846 | 2,195 | 4,036 | 3,107 |
| TOTAL | $356,705 | $357,117 | $362,588 | $340,724 | $256,131 |
| Non-Current Assets | |||||
| PPE Net | 2,314 | 2,393 | 2,241 | 1,338 | 1,468 |
| Investments And Advances | 3,000 | 3,000 | 3,000 | 0 | 631 |
| Intangibles | 8,326 | 8,567 | 3,667 | 3,767 | 3,867 |
| Other Non-Current Assets | 6,646 | 5,223 | 5,348 | 3,449 | 3,394 |
| TOTAL | $20,286 | $19,183 | $14,256 | $8,554 | $9,360 |
| Total Assets | $376,991 | $376,300 | $376,844 | $349,278 | $265,491 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,419 | 54,543 | 43,526 | 36,570 | 23,691 |
| TOTAL | $80,612 | $65,868 | $51,571 | $42,528 | $36,936 |
| Non-Current Liabilities | |||||
| Long Term Debt | 71,845 | 71,708 | 71,578 | 29,933 | 29,819 |
| Other Non-Current Liabilities | 0 | 1,240 | 1,449 | 1,606 | 1,748 |
| TOTAL | $71,845 | $72,948 | $73,027 | $31,539 | $31,567 |
| Total Liabilities | $152,457 | $138,816 | $124,598 | $74,067 | $68,503 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 38,377 | 38,227 | 38,042 | 37,782 | 34,219 |
| Common Shares | 6 | 6 | 6 | 6 | 5 |
| Retained earnings | -360,210 | -337,097 | -313,677 | -280,387 | -244,656 |
| Other shareholders' equity | 179 | 346 | -176 | -63 | -2 |
| TOTAL | $224,534 | $237,484 | $252,246 | $275,211 | $196,988 |
| Total Liabilities And Equity | $376,991 | $376,300 | $376,844 | $349,278 | $265,491 |